PMID- 38138520
OWN - NLM
STAT- MEDLINE
DCOM- 20231225
LR  - 20231225
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 28
IP  - 24
DP  - 2023 Dec 10
TI  - Study of the Mechanism of Astragali Radix in Treating Type 2 Diabetes Mellitus 
      and Its Renal Protection Based on Enzyme Activity, Network Pharmacology, and 
      Experimental Verification.
LID - 10.3390/molecules28248030 [doi]
LID - 8030
AB  - Astragali Radix (AR) is a common Chinese medicine and food. This article aims to 
      reveal the active role of AR in treating Type 2 diabetes mellitus (T2DM) and its 
      renal protective mechanism. The hypoglycemic active fraction was screened by 
      alpha-glucosidase and identified by UPLC-QE-Orbitrap-MS spectrometry. The targets and 
      KEGG pathway were determined through the application of network pharmacology 
      methodology. Molecular docking and molecular dynamics simulation technology were 
      used for virtual verification. Subsequently, a mouse model of T2DM was 
      established, and the blood glucose and renal function indexes of the mice after 
      administration were analyzed to further prove the pharmacodynamic effect and 
      mechanism of AR in the treatment of T2DM. HA was determined as the best 
      hypoglycemic active fraction by the alpha-glucosidase method, with a total of 23 
      compounds identified. The main active components, such as 
      calycoside-7-O-beta-D-glucoside, methylnisoline, and formononetin, were revealed by 
      network pharmacology. In addition, the core targets and the pathway have also 
      been determined. Molecular docking and molecular dynamics simulation techniques 
      have verified that components and targets can be well combined. In vivo studies 
      have shown that AR can reduce blood sugar levels in model mice, enhance the 
      anti-inflammatory and antioxidant activities of kidney tissue, and alleviate 
      kidney damage in mice. And it also has regulatory effects on proteins such as 
      RAGE, PI3K, and AKT. AR has a good therapeutic effect on T2DM and can repair 
      disease-induced renal injury by regulating the RAGE/PI3K/Akt signaling pathway. 
      This study provides ideas for the development of new drugs or dietary 
      interventions for the treatment of T2DM.
FAU - Li, Chunnan
AU  - Li C
AUID- ORCID: 0000-0002-4212-0428
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 
      130117, China.
AD  - Jilin Correction Pharmacy New Drug Development Co., Ltd., Changchun 130012, 
      China.
FAU - Zhang, Kaiyue
AU  - Zhang K
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 
      130117, China.
FAU - Liu, Lu
AU  - Liu L
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 
      130117, China.
FAU - Shen, Jiaming
AU  - Shen J
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 
      130117, China.
FAU - Wang, Yuelong
AU  - Wang Y
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 
      130117, China.
FAU - Tan, Yiying
AU  - Tan Y
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 
      130117, China.
FAU - Feng, Xueqin
AU  - Feng X
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 
      130117, China.
FAU - Liu, Wanjie
AU  - Liu W
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 
      130117, China.
FAU - Zhang, Hui
AU  - Zhang H
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 
      130117, China.
FAU - Sun, Jiaming
AU  - Sun J
AD  - Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 
      130117, China.
LA  - eng
GR  - YDZJ202301ZYTS172/Jilin Province Science and Technology Department/
GR  - 2023, NO.36/Project supported by postdoctoral researchers in Jilin Province/
GR  - QNKXJ2-2021+ZR17./Young Scientist Program of "XingLin Scholar Project" of 
      Changchun University of Chinese Medicine/
PT  - Journal Article
DEP - 20231210
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.2.1.20 (alpha-Glucosidases)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Molecular Docking Simulation
MH  - Network Pharmacology
MH  - Phosphatidylinositol 3-Kinases
MH  - Proto-Oncogene Proteins c-akt
MH  - alpha-Glucosidases
MH  - Kidney
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - *Astragalus Plant
MH  - *Drugs, Chinese Herbal/pharmacology
PMC - PMC10745890
OTO - NOTNLM
OT  - Astragali Radix
OT  - T2DM
OT  - UPLC-QE-Orbitrap-MS
OT  - mechanism
OT  - network pharmacology
COIS- Author Chunnan Li was employed by the company Jilin Correction Pharmacy New Drug 
      Development Co., Ltd. The remaining authors declare that the research was 
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2023/12/23 12:44
MHDA- 2023/12/25 06:41
PMCR- 2023/12/10
CRDT- 2023/12/23 01:16
PHST- 2023/11/15 00:00 [received]
PHST- 2023/11/26 00:00 [revised]
PHST- 2023/12/07 00:00 [accepted]
PHST- 2023/12/25 06:41 [medline]
PHST- 2023/12/23 12:44 [pubmed]
PHST- 2023/12/23 01:16 [entrez]
PHST- 2023/12/10 00:00 [pmc-release]
AID - molecules28248030 [pii]
AID - molecules-28-08030 [pii]
AID - 10.3390/molecules28248030 [doi]
PST - epublish
SO  - Molecules. 2023 Dec 10;28(24):8030. doi: 10.3390/molecules28248030.